文献检索文档翻译深度研究
Suppr Zotero 插件Zotero 插件
邀请有礼套餐&价格历史记录

新学期,新优惠

限时优惠:9月1日-9月22日

30天高级会员仅需29元

1天体验卡首发特惠仅需5.99元

了解详情
不再提醒
插件&应用
Suppr Zotero 插件Zotero 插件浏览器插件Mac 客户端Windows 客户端微信小程序
高级版
套餐订阅购买积分包
AI 工具
文献检索文档翻译深度研究
关于我们
关于 Suppr公司介绍联系我们用户协议隐私条款
关注我们

Suppr 超能文献

核心技术专利:CN118964589B侵权必究
粤ICP备2023148730 号-1Suppr @ 2025

Accelerated Atherosclerosis and Management of Cardiovascular Risk in Autoimmune Rheumatic Diseases: An Updated Review.

作者信息

Karakasis Paschalis, Patoulias Dimitrios, Stachteas Panagiotis, Lefkou Eleftheria, Dimitroulas Theodoros, Fragakis Nikolaos

机构信息

Second Department of Cardiology, Aristotle University of Thessaloniki, General Hospital "Hippokration," Thessaloniki, Greece.

Second Department of Cardiology, Aristotle University of Thessaloniki, General Hospital "Hippokration," Thessaloniki, Greece; Outpatient Department of Cardiometabolic Medicine, Second Department of Cardiology, Aristotle University of Thessaloniki, General Hospital "Hippokration," Thessaloniki, Greece; Second Department of Internal Medicine, European Interbalkan Medical Center, Thessaloniki, Greece.

出版信息

Curr Probl Cardiol. 2023 Dec;48(12):101999. doi: 10.1016/j.cpcardiol.2023.101999. Epub 2023 Jul 26.


DOI:10.1016/j.cpcardiol.2023.101999
PMID:37506959
Abstract

Even though diagnosis and management pathways have been substantially improved over the last years, autoimmune rheumatic diseases (AIRDs) such as rheumatoid arthritis, systemic sclerosis, systemic lupus erythematosus, antiphospholipid syndrome, Sjögren's syndrome, and systemic vasculitides have been linked to elevated rates of cardiovascular morbidity and mortality, primarily secondary to accelerated atherosclerosis. This phenomenon can be partially attributed to the presence of established cardiovascular risk factors but may also be a result of other inflammatory and autoimmune mechanisms that are enhanced in AIRDs. According to the current guidelines, the recommendations regarding cardiovascular disease prevention in patients with AIRDs are not significantly different from those applied to the general population. Herein, we present a review of the current literature on the risk of accelerated atherosclerosis in AIRDs and provide a summary of available recommendations for the management of cardiovascular risk in rheumatic diseases.

摘要

相似文献

[1]
Accelerated Atherosclerosis and Management of Cardiovascular Risk in Autoimmune Rheumatic Diseases: An Updated Review.

Curr Probl Cardiol. 2023-12

[2]
Cardio-Rheumatology: Two Collaborating Disciplines to Deal with the Enhanced Cardiovascular Risk in Autoimmune Rheumatic Diseases.

Curr Vasc Pharmacol. 2020

[3]
Cardio-Rheumatology: Cardiovascular Complications in Systemic Autoimmune Rheumatic Diseases / Is Inflammation the Common Link and Target?

Curr Vasc Pharmacol. 2020

[4]
Cardiorheumatology: cardiac involvement in systemic rheumatic disease.

Nat Rev Cardiol. 2015-3

[5]
EULAR recommendations for cardiovascular risk management in rheumatic and musculoskeletal diseases, including systemic lupus erythematosus and antiphospholipid syndrome.

Ann Rheum Dis. 2022-6

[6]
The Cardio-Rheumatology Approach to Atherosclerotic Cardiovascular Disease.

Reumatol Clin (Engl Ed). 2020

[7]
The role of aspirin in the primary prevention of accelerated atherosclerosis in systemic autoimmune rheumatic diseases.

Rheumatology (Oxford). 2020-12-1

[8]
[Cardiovascular risk in rheumatic diseases].

Cas Lek Cesk. 2016

[9]
Clinical aspects of autoimmune rheumatic diseases.

Lancet. 2013-8-31

[10]
Primary Sjögren's Syndrome and Cardiovascular Disease.

Curr Vasc Pharmacol. 2020

引用本文的文献

[1]
Reprogramming Atherosclerosis: Precision Drug Delivery, Nanomedicine, and Immune-Targeted Therapies for Cardiovascular Risk Reduction.

Pharmaceutics. 2025-8-7

[2]
GLP-1 Receptor Agonists and Myocardial Perfusion: Bridging Mechanisms to Clinical Outcomes.

Int J Mol Sci. 2025-3-26

[3]
Diabetes-Driven Atherosclerosis: Updated Mechanistic Insights and Novel Therapeutic Strategies.

Int J Mol Sci. 2025-2-28

[4]
Aberrant lipid profiles and lymphocyte counts in systemic sclerosis population, reassessing predictive value for concurrent cardiovascular diseases.

Front Immunol. 2025-2-19

[5]
Residual Traditional Risk in Non-Traditional Atherosclerotic Diseases.

Int J Mol Sci. 2025-1-10

[6]
Future atherosclerotic cardiovascular disease in systemic lupus erythematosus based on CSTAR (XXVIII): the effect of different antiphospholipid antibodies isotypes.

BMC Med. 2025-1-6

[7]
Autoimmune diseases and cardiovascular risk: Mendelian randomization analysis for the impact of 19 autoimmune diseases on 14 cardiovascular conditions.

J Transl Autoimmun. 2024-11-1

[8]
Classical and Novel Lipid-Lowering Therapies for Diabetic Patients with Established Coronary Artery Disease or High Risk of Coronary Artery Disease-A Narrative Clinical Review.

Pharmaceuticals (Basel). 2024-4-29

[9]
Vascular Alterations Following COVID-19 Infection: A Comprehensive Literature Review.

Life (Basel). 2024-4-24

[10]
Increased LL37 in psoriasis and other inflammatory disorders promotes LDL uptake and atherosclerosis.

J Clin Invest. 2024-3-1

文献AI研究员

20分钟写一篇综述,助力文献阅读效率提升50倍

立即体验

用中文搜PubMed

大模型驱动的PubMed中文搜索引擎

马上搜索

推荐工具

医学文档翻译智能文献检索